Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Craig

Otolaryngology Detroit, MI Medical Doctor

NPI 1770717456 CMS profile 784079

2799 W Grand Blvd, Detroit, MI 48202

Open in the dashboard

General payments

$39,332

89 records reported · program years 2019–2025

Research payments

$31,700

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Craig of Detroit, MI is reported in the CMS Open Payments database as having received $39,332 across 89 general payments and $31,700 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,354 16
2025 Research $29,362 7
2024 General $5,018 14
2024 Research $2,338 1
2023 General $19,370 44
2022 General $563 5
2021 General $312 3
2020 General $157 4
2019 General $559 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Craig
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to John Craig were reported at $13,354. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year John Craig Otolaryngology median Middle half National median
2019 $559 $194 $82–$512 $163
2020 $157 $118 $42–$280 $114
2021 $312 $167 $63–$444 $132
2022 $563 $216 $84–$545 $149
2023 $19,370 $235 $93–$588 $160
2024 $5,018 $280 $111–$699 $164
2025 $13,354 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerin Medical Inc. $21,952 23 payments
  2. Medtronic, Inc. $13,574 30 payments
  3. Integra LifeSciences Corporation $895 8 payments
  4. Acclarent, Inc $884 8 payments
  5. Intersect ENT, Inc. $732 8 payments
  6. Regeneron Healthcare Solutions, Inc. $560 6 payments
  7. OptiNose US, Inc. $400 1 payment
  8. Cochlear Americas $134 1 payment
  9. Stryker Corporation $122 3 payments
  10. GlaxoSmithKline, LLC. $79 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,240 3 payments
  2. Consulting Fee $13,587 9 payments
  3. Food and Beverage $5,047 61 payments
  4. Travel and Lodging $2,459 16 payments
Products named General payments · program years 2019–2025
  1. VIVAER STYLUS $21,836 21 payments
  2. MIDAS REX $13,316 27 payments
  3. RHINAER STYLUS $1,594 12 payments
  4. ACCLARENT AERA $753 7 payments
  5. INSPIRA AIR $753 7 payments
  6. RELIEVA SPINPLUS NAV $753 7 payments
  7. TruDi Probe $753 7 payments
  8. TruDi NAV Cable $643 5 payments
  9. Xhance $400 1 payment
  10. SINUVA $319 3 payments
  11. Other $2,904 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Aerin Medical Inc. $31,700 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

393

Median for Otolaryngology: 297

Drug cost

$7,995

Median for Otolaryngology: $6,314

Branded share of claims

19.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 212 $5,920
Omeprazole Generic 58 $1,012
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 54 $558
Fluticasone Propionate Generic 25 $340
Prednisone Generic 22 $103
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 22 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$41,202

Medicare's payments for the services billed

Medicare patients

134

Average age 70

Services billed

421

79 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 53%
Ischemic heart disease 29%
Diabetes 28%
Depression 28%
Chronic kidney disease 25%
COPD 22%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record